Financial reports
10-K
2023 FY
Annual report
26 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
25 Apr 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K
2021 FY
Annual report
28 Feb 22
Current reports
8-K
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
1 Mar 24
8-K
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
26 Feb 24
8-K
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
8 Nov 23
8-K
Other Events
6 Nov 23
8-K
Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2 Nov 23
8-K
Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 23
8-K
Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update
4 May 23
8-K
Other Events
21 Mar 23
8-K
Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
28 Feb 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
1 Mar 24
424B5
Prospectus supplement for primary offering
28 Feb 24
424B5
Prospectus supplement for primary offering
26 Feb 24
424B5
Prospectus supplement for primary offering
8 Nov 23
424B5
Prospectus supplement for primary offering
7 Nov 23
S-3ASR
Automatic shelf registration
3 Nov 23
S-8
Registration of securities for employees
21 Jun 23
424B5
Prospectus supplement for primary offering
15 Jul 21
424B5
Prospectus supplement for primary offering
12 Jul 21
S-8
Registration of securities for employees
16 Jun 21
Proxies
DEF 14A
Definitive proxy
25 Apr 23
DEF 14A
Definitive proxy
26 Apr 22
DEF 14A
Definitive proxy
27 Apr 21
DEF 14A
Definitive proxy
28 Apr 20
DEFA14A
Additional proxy soliciting materials
7 May 19
DEF 14A
Definitive proxy
26 Apr 19
DEF 14A
Definitive proxy
30 Apr 18
PRE 14A
Preliminary proxy
19 Apr 18
DEF 14A
Definitive proxy
28 Apr 17
PRE 14A
Preliminary proxy
17 Apr 17
Other
EFFECT
Notice of effectiveness
15 Jun 20
CORRESP
Correspondence with SEC
12 Jun 20
UPLOAD
Letter from SEC
12 Dec 19
CT ORDER
Confidential treatment order
20 Apr 18
EFFECT
Notice of effectiveness
13 Feb 17
EFFECT
Notice of effectiveness
13 Feb 17
CORRESP
Correspondence with SEC
9 Feb 17
CORRESP
Correspondence with SEC
9 Feb 17
UPLOAD
Letter from SEC
6 Feb 17
CORRESP
Correspondence with SEC
12 Jan 17
Ownership
4
Freddy A. Jimenez
15 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G
Kynam Capital Management, LP
14 Feb 24
SC 13G
EVENTIDE ASSET MANAGEMENT, LLC
14 Feb 24
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G
Polar Capital Holdings Plc
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24